CEO Update - 11 March 2024

Spring Budget 2024 – key life science announcements

The Chancellor's Budget last week had plenty for UK life sciences. The BIA’s mission to unlock pension funds for investment into UK life sciences took a great leap forward with the announcement that the life sciences team of Intermediate Capital Group (ICG) has successfully partnered with Phoenix Group, the UK’s largest pensions provider, with the support of the Government’s Long-term Investment for Technology and Science (LIFTS) initiative.

Many of you joined our engaging webinar on "Life sciences and politics in Spring 2024," where we dissected the latest news with the BIA's Martin Turner. You can now catch up on the key takeaways in this excellent blog post and watch the recording for a deeper dive.

All the Spring Budget documents and the Chancellor’s speech can be found on the Treasury website.

The WHO declared COVID-19 a pandemic four years ago today

As the pandemic recedes into the rearview mirror of recent history it was good to hear Kate Bingham on the BBC Radio 4's Today program this morning give a realistic assessment of where we are now as a country. Kate’s interview starts two hours 38 minutes into the show. This week we've also seen the draft negotiating text for a pandemic agreement published online by KEI, the discussion of this text will continue until the World Health Assembly and I am attending an all-party parliamentary group meeting today where I will be stressing the importance of practical measures to scale up production and distribution are at the front of any future agreement.

New Chair for TenU

Congratulations to Tim Haines who has been appointed the new Chair of TenU. TenU is an international collaboration formed to capture effective practices in research commercialisation and share these with governments and higher education communities. Its members work together to increase the societal impact of research.

BIA in Cambridge, Scotland and Brussels this week

It's a really busy week of meetings and I'm really sorry that commitments to EuropaBio in Brussels keep me from both Scotland’s Life Sciences Annual Awards and Dinner and our excellent Women in Biotech networking event scheduled tomorrow for Cambridge. It's great to see the vibrancy of our sector around the country and I know the networks that are being built will stand all participants in good stead for the future. 

Deep dive into Deep Biotech at IBioIC

Join the BIA’s Linda Bedenik and George Caterer at the IBioIC 10th anniversary conference, the UK's biggest industrial biotech event taking place in Glasgow on 13 and 14 March. Catch us at our stand with our sponsors throughout the conference, we’ll be showcasing our Deep Biotech report at the Industrial Biotechnology Leadership Forum (IBLF) and attending the Scottish life sciences dinner. It's the perfect opportunity to discuss the future of Deep Biotech and how we can work together to unlock its potential.

Read our latest blog on the concept of Deep Biotech and how advancements in biotechnology offer solutions to sustainability challenges like plastic waste and fossil fuel reliance.

Jobs at BIA

Have you looked at the BIA's jobs board recently? Not only are there some great opportunities amongst member companies but we are also hiring. If you fancy a role with a bird's eye view across the sector delivering real impact in a not-for-profit format, we'd love to hear from you.


Steve Bates Headshot.png



Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with positive pre-clinical data

Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer.

Coulter Partners top hires for VC & PE portfolio companies Q1-2024

Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.

Abzena announces major investment in bioconjugation and ADC capabilities in response to increasing industry demand

Abzena announced a significant expansion of their Bristol, PA bioconjugate development and cGMP manufacturing site. The $5 million investment in expanded laboratory space, new equipment, and facility upgrades, builds upon the site’s existing bioconjugation capabilities and increases capacity to support the delivery of fully integrated biopharmaceutical drug programs.

CEO Update - 8 April 2024

I don’t always start Newscast with a technical detail – but this one matters and underpins the work of many, many companies in our Association. In short, keep doing your experiments and manufacturing medicines as normal as we work hard to keep your reagents and materials supply chain operating smoothly.

How to build a high-performance life science team

In this blog, Olivia Fletcher-Hogg, Programme Manager at Pioneer Group, provides actionable insights for building high-performance teams in the life sciences and biotech sector, from fostering a positive work culture to empowering employee development.

New £6.2 million partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya

A new £6.2 million healthcare project has begun in Kenya to advance elimination of visceral leishmaniasis, a deadly parasitic disease found in Africa, the Americas, the Middle East and South-East Asia, which affects up to 90,000 children and vulnerable people globally.

AI in life sciences: regulating AI technologies and the product liability implications

Recent regulatory developments in the EU and UK suggest a proactive stance on governing AI technologies, with the EU introducing comprehensive regulations and the UK proposing reforms to align with emerging digital technologies.

New study explores how Switzerland can maintain its leading position in life science innovation

The RSA Group, a leading life sciences executive search firm, has published the latest of its Talent Equity Reports: “Sustaining a winning position”, an analysis of how Switzerland can continue to lead the life sciences sector in a shifting global market.

Data from Brainomix’s collaboration with AstraZeneca shows e-Lung better identifies lung fibrosis patients at risk of decline

Brainomix and AstraZeneca partnered to analyze the Phase 2 tralokinumab clinical trial data of Idiopathic Pulmonary Fibrosis (IPF) patients, leveraging Brainomix’s AI-powered e-Lung software and biomarkers to uncover novel insights. Published data shows e-Lung could play a role in stratifying patients in clinical trials most at risk of decline, outperforming current standard measures.

Eight things we learned about commercialising medical research at Imperial's 'All You Can Innovate' 2024

Why to channel Scottish polymath Mary Somerville, how timing can make or break a startup, and other lessons from experts at All You Can Innovate 2024.

PrecisionLife and NATA announce R&D partnership to jointly develop new motor neurone disease

Leading precision medicine and nucleic acid therapy (NAT) innovators will harness their platforms to develop NAT drug candidates for novel gene targets with strong genetic association to sporadic ALS. The programme will be supported by mechanism-based patient stratification biomarkers to identify likely responders and accelerate and derisk clinical development.

Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team

Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director.

More within